Robust efficacy and long-lasting humoral immunity induced by a respiratory syncytial virus prefusion F-based nanoparticle vaccine in genetically diverse animal models

Abstract

Abstract Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in children, accounting for 7% of deaths in those less than one year of age. Despite multiple exposures to RSV throughout life, natural infection affords only partial protection and there is currently no licensed vaccine against RSV. We developed a vaccine candidate, RSVNanoVax, composed of polyanhydride nanoparticles encapsulating the RSV prefusion F protein and a CpG1668 adjuvant. To assess the efficacy of RSVNanoVax we utilized two model systems with increased genetic variability, Swiss Webster mice and the cotton rat. Following an intranasal prime-boost vaccination with RSVNanoVax, Swiss Webster mice exhibited robust titers of RSV F-directed IgG antibodies in both the serum and lung tissue that were sustained out to at least 1-year post-vaccination. RSV F-directed IgA was also induced within the lung tissue and nasal passages, suggesting that RSVNanoVax stimulates long-lasting systemic and mucosal antibody responses in outbred mice. Serum antibodies maintained robust neutralizing activity against both RSV A and B virus strains. Following RSV challenge, vaccinated mice exhibited complete viral clearance in the lungs as early as day 2 post-infection. Further studies performed in cotton rats demonstrated that RSVNanoVax conferred protection from both viral replication in the lungs as well as RSV-induced pulmonary immunopathology following viral challenge. Vaccinated cotton rats also exhibited robust titers of RSV F-directed serum antibodies with neutralizing capacity. Overall, RSVNanoVax represents a promising RSV vaccine candidate capable of providing long-term protection and immunity in genetically diverse populations. Supported by grants from NIH (R01 AI124093, T32 CA078586, T32 AI007485)